Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer

Expert Opinion on Biological Therapy

Volumn 9, Issue 3, 2009, Pages 331-339

  Morse, Michael A ^a   Hall, Joseph Robert ^a   Plate, Janet M D ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical trials; IL 10; Immunosuppression; Microenvironment; Myeloid derived suppressor cells (MDSC); OX40; Regulatory T cells (Tregs); TGF ; Toll like receptors (TLRs); Tumor products; Tumor associated macrophages (TAMs); Vaccine

Indexed keywords

AP 12009; CANCER VACCINE; CD40 LIGAND; CELL PROTEIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYTOKINE; DENILEUKIN DIFTITOX; FAS LIGAND; GEMCITABINE; INTERLEUKIN 10; LY 2109761; METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MUCIN 1; PEPTIDE VACCINE; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL KILLING; CELLULAR DISTRIBUTION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG TARGETING; ESOPHAGUS CANCER; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MICROENVIRONMENT; NONHUMAN; PANCREAS CANCER; PANCREAS CARCINOMA; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; PANCREAS TUMOR; PHYSIOLOGY;

ANIMALS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; PANCREATIC NEOPLASMS;

EID: 65549136785     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802715756     Document Type: Review

References (91)

1. Plate JM. Current immunotherapeutic strategies in pancreatic cancer. Surg Oncol Clin N Am 2007;16:919-943 (Pubitemid 350101277)
2. Plate JM, Harris JE. Immune cell functions in pancreatic cancer. Crit Rev Immunol 2000;20:375-392 (Pubitemid 32104092)
3. Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res 2007;67:9518-9527 •• Evidence is presented that suppressive cells of the host immune system appear early during pancreatic tumorigenesis, preceding antitumor cellular immunity from the earliest stages. (Pubitemid 47535942)
4. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008;68:2561-2563 • Evidence is presented that myeloid-derived suppressor cells play a major role in creating the immunosuppressive environment by post-translational modifi cation of CD8+ T cell receptors on the T-cell surface.
5. Bellone G, Carbone A, Smirne C, et al. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol 2006;177:3448-3460 (Pubitemid 44277866)
6. Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006;25:315-322 (Pubitemid 44922352)
7. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002;196:254-265 (Pubitemid 34189413)
8. Pan PY, Wang GX, Yin B, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008;111:219-228
9. Chang YC, Chen TC, Lee CT, et al. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 2008;111:5054-5063
10. Tsuji S, Hosotani R, Yonehara S, et al. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int J Cancer 2003;106:17-25 (Pubitemid 36750383)
11. Yang CR, Hsieh SL, Teng CM, et al. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res 2004;64:1122-1129 (Pubitemid 38176919)
12. You RI, Chang YC, Chen PM, et al. Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood 2008;111:1480-1488 (Pubitemid 351213436)
13. Chang YC, Hsu TL, Lin HH, et al. Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 2004;75:486-494 (Pubitemid 38316380)
14. Wu YY, Chang YC, Hsu TL, et al. Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3. J Biol Chem 2004;279:44211-44218 (Pubitemid 39390728)
15. El-Rayes BF, Ali S, Philip PA, Sarkar FH. Protein kinase C: a target for therapy in pancreatic cancer. Pancreas 2008;36:346-352 (Pubitemid 351591576)
16. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007;13:108-116 (Pubitemid 46341958)
17. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-2761 (Pubitemid 34921025)
18. + regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst 2007;99:1188-1199 • Evidence is presented that the selective recruitment of Tregs by tumor-derived endothelial cells is in part due to addressins expressed by tumor cells.
19. Hinz S, Pagerols-Raluy L, Oberg HH, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007;67:8344-8350 (Pubitemid 47395173)
20. Morse MA, Hobeika AC, Osada T, et al. Depletion of human regulatory T cells specifi cally enhances antigen-specifi c immune responses to cancer vaccines. Blood 2008;112:610-618
21. Poch B, Lotspeich E, Ramadani M, et al. Systemic immune dysfunction in pancreatic cancer patients. Langenbecks Arch Surg 2007;392:353-358 (Pubitemid 46675798)
22. Bellone G, Smirne C, Mauri FA, et al. Cytokine expression profi le in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006;55:684-698 •• Evidence was obtained that Pancreatic cancer is characterized by a cytokine expression profi le associated with different survival probabilities, the most important of these cytokines most likely being TGFβ. (Pubitemid 43312164)
23. Terabe M, Matsui S, Park JM, et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198:1741-1752 (Pubitemid 37494166)
24. Li MO, Flavell RA. TGF-β: a master of all T cell trades. Cell 2008;134:392-404
25. Shevach E, Davidson T, Huter E, et al. Role of TGF-β in the induction of Foxp3 expression and T regulatory cell function. J Clin Immunol 2008;28:640-646
26. Hilbig A, Seufferlein T, Schmid RM, et al. Preliminary results of a Phase I/II study in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma using systemic i.v. administration of AP 12009 [abstract 4621]. J Clin Oncol 2008;26 (Suppl)
27. Melisi D, Ishiyama S, Sclabas GM, et al. LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008;7:829-840 (Pubitemid 351551036)
28. Shurin MR, Yurkovetsky ZR, Tourkova IL, et al. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumour-derived IL-10. Int J Cancer 2002;101:61-68 (Pubitemid 34832998)
29. Ryschich E, Marten A, Schmidt E, et al. Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer. Eur J Cancer 2006;42:981-987
30. Serba S, Schmidt J, Wentzensen N, et al. Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma. Gut 2008;57:344-351 (Pubitemid 351288101)
31. Levi E, Klimstra DS, Andea A, et al. MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol 2004;57:456-462 (Pubitemid 38621788)
32. Hiltbold EM, Vlad AM, Ciborowski P, et al. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 2000;165:3730-3741 (Pubitemid 32057279)
33. Tinder TL, Subramani DB, Basu GD, et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 2008;181:3116-3125
34. Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54:254-264 (Pubitemid 40174243)
35. Yamamoto K, Ueno T, Kawaoka T, et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 2005;25:3575-3579 (Pubitemid 41105243)
36. Kawaoka T, Oka M, Takashima M, et al. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncol Rep 2008;20:155-163
37. Kondo H, Hazama S, Kawaoka T, et al. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res 2008;28:379-387
38. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-235
39. Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem 2007;7:599-608
40. Xu XF, Xie CG, Wang XP, et al. Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo. Tohoku J Exp Med 2008;215:149-157
41. Jing H, Vassiliou E, Ganea D. Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells. J Leukoc Biol 2003;74:868-879
42. Jing H, Yen JH, Ganea D. A novel signaling pathway mediates the inhibition of CCL3/4 expression by PGE2. J Biol Chem 2004;279:55176-55186
43. Takayama K, Garcia-Cardena G, Sukhova GK, et al. Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 2002;277:44147-44154
44. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 2006;25:357-371
45. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545
46. Bottazzi B, Polentarutti N, Acero R, et al. Regulation of the macrophage content of neoplasms by chemoattractants. Science 1983;220:210-212
47. Salcedo R, Zhang X, Young HA, et al. Angiogenic effect? of prostaglandin E2 are mediated by up-regulation of CXCR4 on human microvascular endothelial cells. Blood 2003;102:1966-1977
48. Hart CA, Brown M, Bagley S, et al. Invasive characteristics of human prostatic epithelial cells: understanding the metastatic process. Br J Cancer 2005;92:503-512
49. Harris SG, Padilla J, Koumas L, et al. Prostaglandins as modulators of immunity. Trends Immunol 2002;23:144-150
50. Shreedhar V, Giese T, Sung VW, et al. A cytokine cascade including prostaglandin E2, IL-4, and IL-10 is responsible for UV-induced systemic immune suppression. J Immunol 1998;160:3783-3789
51. Huang M, Stolina M, Sharma S, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-1216
52. Della Bella S, Molteni M, Compasso S, et al. Differential effects of cyclo-oxygenase pathway metabolites on cytokine production by T lymphocytes. Prostaglandins Leukot Essent Fatty Acids 1997;56:177-184
53. Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003;111:727-735
54. Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983;3:295-315
55. Sheng H, Shao J, Morrow J, et al. Modulation of apoptosis by prostaglandin treatment in human colon cancer cells. Cancer Res 1998;58:362-366
56. Poligone B, Baldwin AS. Positive and negative regulation of NF-κB by COX-2: roles of different prostaglandins. J Biol Chem 2001;276:38658-38664
57. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-370
58. Yao M, Kargman S, Lam EC, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003;63:586-592
59. Hasan S, Satake M, Dawson DW, et al. Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas 2008;37:121-127
60. Elnemr A, Ohta T, Yachie A, et al. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape. Int J Oncol 2001;18:33-39
61. Ohta T, Elnemr A, Kitagawa H, et al. Fas ligand expression in human pancreatic cancer. Oncol Rep 2004;12:749-754
62. Satoh K, Shimosegawa T, Masamune A, et al. Fas ligand is frequently expressed in human pancreatic duct cell carcinoma. Pancreas 1999;19:339-345
63. von Bernstorff W, Spanjaard RA, Chan AK, et al. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 1999;125:73-84
64. Tamura H, Ogata K, Dong H, Chen L. Immunology of B7-H1 and its roles in human diseases. Int J Hematol 2003;78:321-328
65. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13:2151-2157
66. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and Tcell activation. Nature 2002;419:734-738
67. Xu X, Rao G, Gaffud MJ, et al. Clinicopathologic significance of major histocompatibility complex class I-related chain A and B (MICA/B) expression in thyroid cancer. J Clin Endocrinol Metab 2006;91:2704-2712
68. Bloomston M, Zervos EE, Rosemurgy AS. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 2002;9:668-674
69. Pino SM, Xiong HQ, McConkey D, Abbruzzese JL. Novel therapies for pancreatic adenocarcinoma. Curr Gastroenterol Rep 2004;6:119-125
70. Waldhauer I, Goehlsdorf D, Gieseke F, et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008;68:6368-6376
71. Fridman JS, Caulder E, Hansbury M, et al. Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 2007;13:1892-1902
72. Witkiewicz A, Williams TK, Cozzitorto J, et al. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection. J Am Coll Surg 2008;206:849-54; discussion 854-856 Published online 4 March 2008, doi:10.1016/j.jamcollsurg. 2007.12.014
73. Rodríguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008;222:180-191
74. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839-5849
75. Jaffee EM, Schutte M, Gossett J, et al. Development and characterization of a cytokine secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 1998;4:194-203
76. Jaffee EM, Hruban R, Biedrzycki B, et al. A novel allogeneic GM-CSF secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-156
77. Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008;14:1455-1463
78. Petrulio CA, Kaufman HL. Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev Vaccines 2006;5:9-19
79. Rasmussen H, Rasmussen C, Lempicki M, et al. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002;9:951-957
80. Arancibia SA, Beltán CJ, Aguirre IM, et al. Toll-like receptors are key participants in ?nnate immune responses. Biol Res 2007;40:97-112
81. Berd D, Maguire H, Mastrangelo M. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 1986;46:2572-2577
82. + Tcells to the antitumor immune response. J Exp Med 2005;201:1591-1602
83. Ambrosino E, Spadaro M, Iezzi M, et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006;66:7734-7740
84. Kusmartsev S, Cheng F, Yu B, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003;63:4441-4449
85. De Santo C, Serafini P, Marigo I, et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc Natl Acad Sci USA 2005;102:4185-4190
86. Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006;203:2691-2702
87. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004;64:5839-5849
88. Degrate L, Nobili C, Franciosi C, et al. Interleukin-2 immunotherapy action on innate immunity cells in peripheral blood and tumoral tissue of pancreatic adenocarcinoma patients. Langenbecks Arch Surg 2009;394:115-121
89. Evelien L, Smits JM, Ponsaerts P, et al. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. The Oncologist 2008;13:859-875
90. Clark RA, Huang SJ, Murphy GF, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008;205:2221-2234
91. Schmidt J, Welsch T, Mühlradt PF, et al. Intratumoral injection of macrophage-activating lipopeptide (MALP-2) in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer 2007;97:598-604